Product
*Actual vial appearance, contents, and dosage may vary and is based on your prescription.

GLP-1/NAD+ Oral Drops

The GLP-1/ NAD+ Oral Drop offers powerful support in a convenient, needle-free dose, designed to help promote weight loss, reduce appetite, boost energy, and support metabolic and cellular health. Just swish in your mouth, no injections, no refrigeration, and no daily routine, making it an effortless fit for your lifestyle. Powered by EllievaTec™, a proprietary Advanced Absorption Technology studied for over a decade, this advanced system is designed for effective delivery through the mouth, so you get more from every drop.
Free Shipping

Free Shipping

info-icon
Medical Consultation Included

Medical Consultation Included

info-icon
  • State-Specific Eligibility: Availability varies by state.
    • No Injections, No Daily Routine – Enjoy GLP-1/NAD+ support in a simple oral drop, just swish and go!
    • No hidden membership, consultation, or shipping fees
    • A licensed healthcare practitioner in your state will review your assessment and determine your eligibility.

Testimonials

Read what our customers have to say about our products.

Scientific Sources

1. Science-Backed Weight Loss
Study: A 72-week clinical trial found that a GLP-1/GIP receptor agonist led to an average weight loss of up to 22.5%, with over half of participants achieving ≥20% total body weight reduction.
Source:
Tirzepatide Once Weekly for the Treatment of ObesityJastreboff, A. M., et al. (2022). New England Journal of Medicine, 387, 205–216. doi:10.1056/NEJMoa2206038
2. Appetite & Craving Control
Study: A GLP-1/GIP receptor agonist was shown to significantly reduce appetite, energy intake, and body weight in adults with type 2 diabetes.
Source:
Frias, J. P., et al. (2023). Frontiers in Pharmacology, 14, 1453825. doi:10.3389/fphar.2024.1453825
3. Cardiometabolic Support
Study: GLP-1/GIP receptor agonists have been associated with improvements in blood pressure, lipid profiles, and cardiovascular risk markers in individuals with obesity and diabetes.
Source:
Jastreboff, A. M., et al. (2022). New England Journal of Medicine, 387, 205–216. doi:10.1056/NEJMoa2206038
4. Cellular Energy & Metabolic Resilience with NAD+
Study: Human studies using intravenous NAD+ administration have shown increased cellular NAD+ levels in healthy and elderly participants, which is associated with enhanced mitochondrial activity, metabolic support, and cognitive function.
Source:
(2025). The Role of NAD+ in Regenerative Medicine. PMC, 9512238.
5. Off-Label Uses Under Medical Supervision
Study: GLP-1/GIP therapies are being explored off-label for use in PCOS, non-alcoholic fatty liver disease (NAFLD), and obesity-related sleep apnea due to their effects on fat loss, insulin resistance, and metabolic inflammation.
Source:
Frias, J. P., et al. (2023). Frontiers in Pharmacology, 14, 1453825. doi:10.3389/fphar.2024.1453825
6. Advanced Absorption Technology (EllievaTec™ / ALM DT)
Study: The ALM DT delivery system (licensed as EllievaTec™) was used in a dissolving oral granule formula designed for sublingual absorption and body recomposition, demonstrating effective uptake through the mucosal membrane and providing a needle-free alternative to traditional delivery methods.
Source:
Morrison, B. S., & Hesson, S. (2022). Functional Foods in Health and Disease, 12(4), 134–150. doi:10.31989/ffhd.v12i3.905
Study: The ALM DT delivery system (licensed as EllievaTec™) was also utilized in a swish-and-swallow oral formula combining bioflavonoids and electrolytes, which demonstrated enhanced absorption and performance support in athletes.
Source:
Downs, B. W., Banik, S. P., Bagchi, M., Morrison, B. S., Kushner, S., Piacentino, M., & Bagchi, D. (2021). American Journal of Biopharmaceutics and Pharmaceutical Sciences, 1(2). doi:10.25259/AJBPS_2_2021
Study: A sublingual multi-enzyme formula utilizing the ALM DT delivery system (licensed as EllievaTec™) showed promising absorption results and was evaluated for safety and efficacy in a randomized, double-blind, placebo-controlled human trial.
Source:
Bagchi, M., Corbier, J-R., Downs, B. W., Kushner, S., Aloisio, T., & Bagchi, D. (2019). Journal of the American College of Nutrition. doi:10.1080/07315724.2019.1704467

Frequently Asked Questions

Expand the questions below

Get the latest updates and exclusive offers by subscribing to our newsletter.

By subscribing, you agree to our Privacy Policy and consent to receive updates.